James L Riley

List of Publications by Year in Descending Order

128 papers	17,797 citations	64 h-index	130 g-index
130 ext. papers	20,098 ext. citations	12.8 avg, IF	6.35 L-index

#	Paper	IF	Citations
128	Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque.. *Cell Reports Medicine*, **2022**, 3, 100614	18	0
127	Engineering T Cells to Survive and Thrive in the Hostile Tumor Microenvironment. *Current Opinion in Biomedical Engineering*, **2021**, 100360	4.4	1
126	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *Journal of Clinical Investigation*, **2021**, 131,	15.9	15
125	Ultrasensitive antigen density discrimination by synNotch. *Cell Research*, **2021**, 31, 725-726	24.7	
124	Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. *Journal of Infectious Diseases*, **2021**, 223, 38-45	7	8
123	NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation. *Cancer Research*, **2021**, 81, 3241-3254	10.1	2
122	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. *Blood Advances*, **2021**, 5, 1069-1080	7.8	7
121	Genetic engineering of T cells for immunotherapy. *Nature Reviews Genetics*, **2021**, 22, 427-447	30.1	17
120	Selective reactivation of STING signaling to target Merkel cell carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 13730-13739	11.5	15
119	HIV-Resistant and HIV-Specific CAR-Modified CD4 T Cells Mitigate HIV Disease Progression and Confer CD4 T Cell Help In Vivo. *Molecular Therapy*, **2020**, 28, 1585-1599	11.7	12
118	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. *Blood*, **2020**, 136, 1722-1734	2.2	15
117	Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry. *Journal of Immunological Methods*, **2020**, 484-485, 112830	2.5	1
116	Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. *Nature Medicine*, **2020**, 26, 1776-1787	50.5	22
115	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. *Nature Medicine*, **2020**, 26, 1339-1350	50.5	43
114	How to kill T cells for immunotherapy.. *Nature Cancer*, **2020**, 1, 1134-1135	15.4	2
113	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. *Frontiers in Immunology*, **2019**, 10, 2310	8.4	15
112	Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. *Cell Reports*, **2018**, 23, 741-755	10.6	28

111	Role of PD-1 during effector CD8 T cell differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4749-4754	11.5	178
110	Improved Expansion and Function of Patient T Cells by a Serum-free Medium. *Molecular Therapy - Methods and Clinical Development*, **2018**, 8, 65-74	6.4	25
109	Translating In Vitro T Cell Metabolic Findings to In Vivo Tumor Models of Nutrient Competition. *Cell Metabolism*, **2018**, 28, 190-195	24.6	15
108	CAR T cells for infection, autoimmunity and allotransplantation. *Nature Reviews Immunology*, **2018**, 18, 605-616	36.5	101
107	Generation of human islet-specific regulatory T cells by TCR gene transfer. *Journal of Autoimmunity*, **2017**, 79, 63-73	15.5	67
106	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. *Journal of Virology*, **2017**, 91,	6.6	4
105	In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. *American Journal of Transplantation*, **2017**, 17, 3098-3113	8.7	20
104	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. *Journal of Infectious Diseases*, **2017**, 215, S160-S171	7	17
103	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. *Cytotherapy*, **2017**, 19, 250-262	4.8	32
102	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. *PLoS Pathogens*, **2017**, 13, e1006613	7.6	68
101	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. *Journal of Clinical Investigation*, **2016**, 126, 2642-60	15.9	63
100	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. *PLoS Pathogens*, **2016**, 12, e1005983	7.6	26
99	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood*, **2016**, 127, 1044-51	2.2	251
98	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. *Blood*, **2016**, 128, 1424-35	2.2	46
97	Engineering T Cells to Functionally Cure HIV-1 Infection. *Molecular Therapy*, **2015**, 23, 1149-1159	11.7	40
96	Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. *Blood*, **2014**, 123, 61-9	2.2	116
95	Stabilized human TRIM5 protects human T cells from HIV-1 infection. *Molecular Therapy*, **2014**, 22, 1084-1095	11.7	30
94	Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. *Clinical Cancer Research*, **2014**, 20, 4262-73	12.9	256

93	Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. *Journal of Immunology*, **2014**, 192, 2913-9	5.3	19
92	Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. *American Journal of Transplantation*, **2013**, 13, 3010-20	8.7	192
91	The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. *American Journal of Pathology*, **2013**, 183, 1971-80	5.8	23
90	Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. *Human Gene Therapy*, **2013**, 24, 245-58	4.8	99
89	Strength of PD-1 signaling differentially affects T-cell effector functions. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2480-9	11.5	192
88	Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. *Journal of Immunology*, **2013**, 190, 4470-3	5.3	24
87	Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. *Science Translational Medicine*, **2013**, 5, 197ra103	17.5	441
86	The human CD8M-4 isoform dominant in effector memory T cells has distinct cytoplasmic motifs that confer unique properties. *PLoS ONE*, **2013**, 8, e59374	3.7	3
85	TCR affinity and specificity requirements for human regulatory T-cell function. *Blood*, **2012**, 119, 3420-30	2.2	37
84	CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. *Science Translational Medicine*, **2012**, 4, 134ra62	17.5	216
83	Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Science Translational Medicine*, **2012**, 4, 132ra53	17.5	456
82	The battle over mTOR: an emerging theatre in host-pathogen immunity. *PLoS Pathogens*, **2012**, 8, e1002864	7.3	35
81	Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. *Journal of Immunology*, **2012**, 189, 3815-21	5.3	16
80	Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. *Science Translational Medicine*, **2011**, 3, 83ra41	17.5	272
79	Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. *Nature Immunology*, **2011**, 12, 898-907	19.1	145
78	Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. *Immunity*, **2011**, 35, 400-12	32.3	275
77	Clinical perspectives for regulatory T cells in transplantation tolerance. *Seminars in Immunology*, **2011**, 23, 462-8	10.7	87
76	Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. *American Journal of Transplantation*, **2011**, 11, 1148-57	8.7	177

75	Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. *Cancer Immunology, Immunotherapy*, **2011**, 60, 133-44	7.4	21
74	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. *Journal of Translational Medicine*, **2011**, 9, 131	8.5	46
73	The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. *Science Translational Medicine*, **2011**, 3, 111ra120	17.5	286
72	Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. *Clinical Cancer Research*, **2011**, 17, 4719-30	12.9	363
71	Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. *PLoS Pathogens*, **2011**, 7, e1002020	7.6	118
70	Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. *PLoS ONE*, **2011**, 6, e15868	3.7	109
69	The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. *Science Translational Medicine*, **2010**, 2, 55ra78	17.5	185
68	Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. *PLoS Pathogens*, **2010**, 6, e1001098	7.6	104
67	Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. *PLoS Biology*, **2010**, 8, e1000302	9.7	70
66	HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. *Molecular Therapy*, **2010**, 18, 803-11	11.7	18
65	Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. *Clinical Immunology*, **2010**, 136, 348-63	9	103
64	Engineering lymphocyte subsets: tools, trials and tribulations. *Nature Reviews Immunology*, **2009**, 9, 704-16	36.5	156
63	PD-1 signaling in primary T cells. *Immunological Reviews*, **2009**, 229, 114-25	11.3	504
62	Human T regulatory cell therapy: take a billion or so and call me in the morning. *Immunity*, **2009**, 30, 656-65	32.3	358
61	Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Molecular Therapy*, **2009**, 17, 1453-64	11.7	786
60	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3360-5	11.5	637
59	Are affinity-enhanced T cells the future of HIV therapy?. *HIV Therapy*, **2009**, 3, 105-108		1
58	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. *Nature Biotechnology*, **2008**, 26, 808-16	44.5	812

57	Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. *Nature Medicine*, **2008**, 14, 1390-5	50.5	204
56	The paracaspase MALT1 controls caspase-8 activation during lymphocyte proliferation. *Molecular Cell*, **2008**, 31, 415-21	17.6	53
55	CD28 costimulation is essential for human T regulatory expansion and function. *Journal of Immunology*, **2008**, 181, 2855-68	5.3	133
54	Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. *Journal of Immunology*, **2008**, 180, 5794-8	5.3	156
53	Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. *Journal of Virology*, **2008**, 82, 11117-28	6.6	59
52	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. *Blood*, **2008**, 112, 2847-57	2.2	123
51	Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. *PLoS ONE*, **2008**, 3, e3289	3.7	40
50	Genetic engineering of T cells for adoptive immunotherapy. *Immunologic Research*, **2008**, 42, 166-81	4.3	53
49	Adoptive immunotherapy: good habits instilled at youth have long-term benefits. *Immunologic Research*, **2008**, 42, 182-96	4.3	43
48	Engineered ovarian cancer artificial antigen presenting cells (aAPCs) support CD8+T cells growth and function. *FASEB Journal*, **2008**, 22, 519-519	0.9	
47	Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. *Molecular Therapy*, **2007**, 15, 981-8	11.7	206
46	FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. *International Immunology*, **2007**, 19, 825-35	4.9	111
45	Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. *Journal of Virology*, **2007**, 81, 13938-42	6.6	46
44	RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. *Blood*, **2007**, 110, 3226-33	2.2	69
43	Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 1135-44	4.7	27
42	The road to recovery: translating PD-1 biology into clinical benefit. *Trends in Immunology*, **2007**, 28, 48-50	14.4	28
41	Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. *Trends in Immunology*, **2007**, 28, 161-8	14.4	32
40	FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 4571-6	11.5	325

39	Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. *Cancer Research*, **2006**, 66, 1114-22	10.1	82
38	B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. *Journal of Immunology*, **2006**, 176, 6603-14	5.3	68
37	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. *Journal of Clinical Investigation*, **2006**, 116, 174-81	15.9	84
36	Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. *Clinical Immunology*, **2005**, 115, 26-32	9	28
35	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. *Blood*, **2005**, 105, 13-21	2.2	248
34	Ligation of CD28 by its natural ligand CD86 in the absence of TCR stimulation induces lipid raft polarization in human CD4 T cells. *Journal of Immunology*, **2005**, 175, 7848-54	5.3	30
33	CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Molecular and Cellular Biology*, **2005**, 25, 9543-53	4.8	1273
32	Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. *FASEB Journal*, **2004**, 18, 1303-5	0.9	144
31	Extensive replicative capacity of human central memory T cells. *Journal of Immunology*, **2004**, 172, 6675-83	5.3	40
30	SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. *Journal of Immunology*, **2004**, 173, 945-54	5.3	793
29	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.. *Blood*, **2004**, 104, 2657-2657	7.2	4
28	DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. *Virology*, **2003**, 305, 115-23	3.6	296
27	HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. *Clinical Immunology*, **2003**, 106, 16-22	9	57
26	Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. *Journal of Virology*, **2003**, 77, 13433-8	6.6	95
25	CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. *Journal of Immunology*, **2003**, 171, 166-74	5.3	132
24	Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. *Nature Biotechnology*, **2002**, 20, 143-8	44.5	339
23	Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 11790-5	11.5	239
22	Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. *Journal of Immunology*, **2002**, 168, 4272-6	5.3	583

21	Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 15006-11	11.5	52
20	A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. *Clinical Immunology*, **2002**, 105, 259-72	9	70
19	The CD28 signaling pathway regulates glucose metabolism. *Immunity*, **2002**, 16, 769-77	32.3	970
18	ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. *Journal of Immunology*, **2001**, 166, 4943-8	5.3	104
17	Influenza virus upregulates CXCR4 expression in CD4+ cells. *AIDS Research and Human Retroviruses*, **2000**, 16, 19-25	1.6	7
16	CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. *Journal of Experimental Medicine*, **2000**, 191, 651-60	16.6	160
15	Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. *Journal of Experimental Medicine*, **2000**, 191, 1987-97	16.6	48
14	Quantitation of HIV-1 Entry Cofactor Expression. *Methods in Molecular Medicine*, **1999**, 17, 219-26		
13	Constitutive cell surface association between CD4 and CCR5. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 7496-501	11.5	156
12	Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. *Stem Cells and Development*, **1998**, 7, 437-48		99
11	The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. *Seminars in Immunology*, **1998**, 10, 195-202	10.7	21
10	Productive infection of neonatal CD8+ T lymphocytes by HIV-1. *Journal of Experimental Medicine*, **1998**, 187, 1139-44	16.6	72
9	MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression. *American Journal of Reproductive Immunology*, **1998**, 40, 385-94	3.8	37
8	Naïve and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implicatip6s for transmission and pathogenesis. *Journal of Virology*, **1998**, 72, 8273-80	6.6	61
7	Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. *Science*, **1997**, 276, 273-6	33.3	182
6	Response from Carroll et al.. *Trends in Microbiology*, **1997**, 5, 302-303	12.4	3
5	Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. *Science*, **1996**, 272, 1939-43	33.3	199
4	Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). *Immunity*, **1995**, 2, 533-43	32.3	166

3	Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. *Immunity*, **1994**, 1, 687-97	32.3	129
2	Genetically Modified T Cells for Human Gene Therapy193-205		
1	Discovery and Engineering of a Therapeutic Interfering Particle (TIP): a combination self-renewing antiviral		1